175 related articles for article (PubMed ID: 26605208)
1. Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.
Decaestecker K; Oosterlinck W
Res Rep Urol; 2015; 7():157-63. PubMed ID: 26605208
[TBL] [Abstract][Full Text] [Related]
2. Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer.
Liu Y; Lu J; Huang Y; Ma L
J Oncol; 2019; 2019():6230409. PubMed ID: 30984262
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
4. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
5. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
Lamm DL; van der Meijden PM; Morales A; Brosman SA; Catalona WJ; Herr HW; Soloway MS; Steg A; Debruyne FM
J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436
[TBL] [Abstract][Full Text] [Related]
6. Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer.
Vilares AT; Nunes Silva C; Correia da Silva M; Sousa J; Viamonte B; Madureira AJ
Radiol Case Rep; 2022 Jul; 17(7):2383-2387. PubMed ID: 35570860
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin.
Tozawa K; Okamura T; Yamada Y; Hayashi Y; Sasaki S; Kohri K
Asian Pac J Cancer Prev; 2000; 1(3):217-220. PubMed ID: 12718668
[TBL] [Abstract][Full Text] [Related]
8. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma].
Kudo T; Iwasa N; Maeda S; Mitarai S
Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373
[TBL] [Abstract][Full Text] [Related]
9. Practical approaches to the prevention and treatment of adverse reactions to BCG.
van der Meijden AP
Eur Urol; 1995; 27 Suppl 1():23-8. PubMed ID: 7750529
[TBL] [Abstract][Full Text] [Related]
10. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
11. Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.
Sampaio PCM; Lira YG; Ribeiro HYU; de Paula Moreira F; Gadelha MSM; da Cruz SFS
BMC Res Notes; 2017 Aug; 10(1):416. PubMed ID: 28821265
[TBL] [Abstract][Full Text] [Related]
12. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
14. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2010 Nov; 184(5):1920-4. PubMed ID: 20846678
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
18. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N
Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guérin immunotherapy.
Poletajew S; Krajewski W; Adamowicz J; Radziszewski P
Anticancer Drugs; 2019 Jun; 30(5):517-522. PubMed ID: 30870228
[TBL] [Abstract][Full Text] [Related]
20. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R;
J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
